Aldeyra Therapeutics, Inc. (ALDX) 8-K Current Report: March 17, 2026
Filed: March 17, 2026
Health Care
Pharmaceutical PreparationsAldeyra Therapeutics, Inc. (ALDX) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 7.01: Regulation FD Disclosure
Aldeyra Therapeutics, Inc. 8-K Mar 17, 2026 Event Analysis
Item 7.01 · Regulation FD Disclosure
- • FDA issued second Complete Response Letter (2026 CRL) for reproxalap dry eye NDA — cited lack of substantial evidence and "inconsistency of study results"
- • FDA rejected despite prior dry eye chamber trial hitting primary endpoint (P=0.002) — "totality of evidence does not support effectiveness"
- • Aldeyra plans Type A meeting with FDA to determine path forward; additional studies likely required, raising costs and extending timeline materially
- • No assurance FDA will ever approve reproxalap; company may also abandon pursuit for financial or strategic reasons
- • Cash runway extended into 2028 as of Dec 31, 2025 — provides time to navigate regulatory path but approval timeline remains highly uncertain
Get deeper insights on Aldeyra Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.